(Hims & Hers, NYSE: HIMS), the leading health and wellness platform, today shared more data on the challenges Americans are facing when trying to access branded GLP-1 medication and introduced a GLP-1 Supply Tracker, where individuals can be a part of advocating for better access to the medications they need
Since it mimics both GLP-1 and GIP, it may be more effective than semaglutide
How It Works Activates both GLP-1 and GIP receptors for a broader metabolic impact Reduces appetite and increases satiety through two hormonal pathways Enhances insulin sensitivity more aggressively than GLP-1 alone Supports reduction of visceral fat the deep abdominal fat most strongly associated with metabolic disease Improves blood sugar regulation through a dual insulin-stimulating mechanism Clinical Results In the SURMOUNT-1 trial, Tirzepatide produced average weight loss of up to 20% of body weight outperforming Semaglutide in head-to-head comparisons
[DOI] [PubMed] [Google Scholar] 53.Gadde K.M., Yonish G.M., Foust M.S., Allison D.B
M.ZhuM.et al
We know that a person with a history of IBS-D will have a very different experience on Wegovy than someone with IBS-C
